NCT05054114View on ClinicalTrials.gov

Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

NACompletedINTERVENTIONAL

Enrollment

630

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

May 25, 2021

Study Completion Date

September 2, 2021

Conditions

COVID-19 Respiratory InfectionAcute Respiratory Disease

Interventions

DRUG

Interferon gamma human recombinant (IFN-G)

nasal form

Trial Locations (1)

121374

City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow

All Listed Sponsors

lead

SPP Pharmaclon Ltd.

INDUSTRY

NCT05054114 - Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19 | Biotech Hunter | Biotech Hunter